The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis

A. G. Willison · T. Ruck · G. Lenz · H. P. Hartung · S. G. Meuth

Received: 4 February 2022 / Revised: 2 March 2022 / Accepted: 3 March 2022 / Published online: 11 April 2022 © The Author(s) 2022

Abstract

Autologous haematopoietic stem cell transplantation (aHSCT) is gaining traction as a valuable treatment option for patients affected by severe multiple sclerosis (MS), particularly the relapsing–remitting form. We describe the current literature in terms of clinical trials, observational and retrospective studies, as well as immune reconstitution following transplantation, with a focus on the conditioning regimens used for transplantation. The evidence base predominantly consists of non-randomised, uncontrolled clinical trials or data from retrospective or observational cohorts, i.e. very few randomised or controlled trials. Most often, intermediate-intensity conditioning regimens are used, with promising results from both myeloablative and lymphoablative strategies, as well as from regimens that are low and high intensity. Efficacy of transplantation, which is likely secondary to immune reconstitution and restored immune tolerance, is, therefore, not clearly dependent on the intensity of the conditioning regimen. However, the conditioning regimen may well influence the immune response to transplantation. Heterogeneity of conditioning regimens among studies hinders synthesis of the articles assessing post-aHSCT immune system changes. Factors associated with better outcomes were lower Kurtzke Expanded Disability Status Scale, relapsing–remitting MS, younger age, and shorter disease duration at baseline, which supports the guidance for patient selection proposed by the European Society for Blood and Marrow Transplantation. Interestingly, promising outcomes were described for patients with secondary progressive MS by some studies, which may be worth taking into account when considering treatment options for patients with active, progressive disease. Of note, a significant proportion of patients develop autoimmune disease following transplantation, with alemtuzumab-containing regimens associated with the highest incidence.

Keywords

Autologous haematopoietic stem cell transplant · Multiple sclerosis · Immune reconstitution

Introduction

Multiple sclerosis (MS) likely occurs against a background of genetic and environmental predisposition, leading to auto-reactivity of peripheral immune cells, blood brain barrier (BBB) breakdown and central nervous system (CNS) infiltration [1–4]. Subsequent neuronal demyelination and neuroinflammation is facilitated by CNS-resident cells [5, 6]. Offering affected patients perhaps the most impressive series of therapeutic milestones over the past 28 years, MS research is a very encouraging example of bench-to-bedside success, at least for relapsing–remitting multiple sclerosis (RRMS). The progressive forms of MS—secondary progressive MS (SPMS) and primary progressive MS (PPMS)—have demonstrated a less encouraging response to novel treatments in clinical trials [7, 8]. Of note, PPMS may be considered “active” if relapses occur, which would have been referred to as progressive-relapsing MS (PRMS) prior to the publication
of the 2013 International Advisory Committee on Clinical Trials of MS guidelines [9]. SPMS may also be termed “active” with reference to relapse occurrence [10]. These advancements in available treatments have allowed not only for a better understanding of disease pathogenesis, but also for no evidence of disease activity (NEDA) to become a realistic treatment target, particularly using immunomodulatory therapies.

Indeed, the approval of beta interferon (IFN-β) drugs in the 1990s as the first disease-modifying therapy (DMT) for RRMS accelerated MS research towards immunomodulatory approaches by demonstrating the efficacy of cytokine regulation and, as it was later elucidated, alteration of T cell subpopulations [11–14]. This confirmed that T cells did indeed facilitate relapses and could be therapeutically targeted. In this regard, key factors in the occurrence of relapse are thought to be autoreactivity of IL-17 expressing CD4+ T cells (i.e. T helper 17 cells (Th17)), CD4+ T helper 1 cells (Th1), CD8+ T cells and the insufficient function of regulatory T cells (T regs) [15–19], indicating that T cells are clearly important in MS pathogenesis. In addition, the recent advent of B cell-targeting monoclonal antibody therapies has established the critical role of, for example, pro-inflammatory CD20-expressing B cells in the cytokine cascade that characterises a relapse [20, 21] and daclizumab has more recently demonstrated a role for natural killer (NK) cells [22]. Not only does the infiltration of T cells and B cells contribute to relapse occurrence, but also that of macrophages and the activation of CNS-resident cells, including microglia and astrocytes, all of which contributing to pathogenic cytokine networks.

The early, now less efficacious, treatments, namely the IFN-β drugs and glatiramer acetate, still offer good outcomes as well as a favourable safety profile and, therefore, serve as an opener to “escalation therapy”, with severity of disease said to be proportional to the potency of treatment [23–26]. For those affected by particularly aggressive disease at a younger age, the hit hard and hit early approach, which may refer to “induction therapy” or “highly effective treatment early”, instead of escalation therapy is often considered, as efficacy is of the utmost importance for these patients. The key, here, is patient selection. Specifically, patients who will benefit the most from aggressive treatments in terms of disease outcome, i.e. successful immune reprogramming and long-term remission as well as tolerance of side effects are considered the optimal candidates. These highly efficacious treatments work by either sequestrating lymphocytes in lymph nodes, lymphocyte depletion (e.g. the so-called immune reconstitution therapies (IRTs)) or reducing immune cell trafficking into the CNS [27]. Following a short course of these immunomodulatory drugs, patients may then: be given either IFN-β or glatiramer acetate to maintain remission—this would be “induction therapy”; continue with the same immunomodulatory treatment; trial further highly efficacious treatments until symptoms are controlled. Compared to IFN-β and glatiramer acetate, the highly effective therapies have a significant side effect profile but are thought to confer a lower risk of developing SPMS [28, 29] and offer more favourable long-term clinical outcomes [30, 31].

Research being focussed on immunomodulation has, therefore, proven promising and there is good reason to more readily start highly effective immunomodulatory therapy [32]. MS is challenging to prognosticate; the natural history may occur insidiously over many years, of which a good number are often lived with minimal disability, but inflammation accumulates [33]. A patient’s disease burden may be underestimated by standard magnetic resonance imaging (MRI)—take the recently described smouldering lesions, for example, that are better visible with ultra-high field strength MRI but may be seen using 3 T or on histopathological examination [34]. Further, diagnosis is most often made between age 20–40, with these younger patients having fewer co-morbidities and thereby being more resilient to aggressive treatments. In this vein, for younger patients with early disease and lower Kurtzke Expanded Disability Status Scale (EDSS) score, increasing consideration in recent years has been given to autologous haematopoietic stem cell transplantation (aHSCT), a less well-accepted yet strikingly effective form of IRT that may allow for long-term, perhaps even life-long in some cases, cessation of aberrant immune system functioning [35, 36].

Briefly, the aHSCT procedure involves five stages: pre-transplant optimisation (i.e. identification of co-morbidities, infection prophylaxis, and, e.g. admission for pre-hydration); stem cell mobilisation; conditioning (i.e. myelo- or lymphoablation); stem cell reinfusion; post-transplant supportive care (Fig. 1). The conditioning regimens are variable and considered to be myeloablative or lymphoablative/non-myeloablative (Fig. 1). Near-complete or complete destruction of the bone marrow is considered myeloablative and requires the use of high-dose total body irradiation (TBI) or busulfan. A transplanted graft is necessary for these patients, i.e. autologous recovery will not occur [37]. According to the European Society for Blood and Marrow Transplantation (EBMT), the intermediate-intensity regimens can be described as myeloablative or lymphoablative and may include low-dose TBI or busulfan, although, at least in the context of aHSCT for MS, predominantly include BEAM (a combination of carmustine (BCNU), etoposide, cytarabine (Ara-C) and melphalan) with anti-thymocyte globulin (ATG) (BEAM+ATG) for intermediate myeloablative intensity and cyclophosphamide (CY) and ATG (CY+ATG) or CY and alemtuzumab (ALEM) (CY+ALEM) for intermediate lymphoablative intensity [38]. Again, according to the EBMT, low-intensity regimens include chemotherapy without the addition of antibody therapy, i.e.
Autologous transplantation and immune reconstitution. The first step is patient selection, where fitness and suitability for transplant are considered. In patients with MS, autoreactive T cell clones that have escaped immune tolerance mechanisms contribute to pathogenesis by effecting neuroinflammation, along with B cells and natural killer (NK) cells. These cells have common progenitors in the bone marrow, which are—at the earliest—haematopoietic stem cells (HSC), with later stages including multipotent progenitors (MPP) and multi-lymphoid progenitors (MLP). B cell maturation occurs primarily within the bone marrow. T cell maturation occurs within the thymus, with the bone marrow producing thymocytes that then undergo a complex maturation process within the thymus, which is completed in the periphery. The transplanted HSCs then engraft and repopulate the immune system, leading to normalization of TCR repertoire and the expansion of autoreactive clones.
ATG. Note that BEAM regimens used without ATG have, therefore, been considered as low intensity in this review but BEAM was used without ATG in very few trials. These regimens induce cytopenia and some, to a lesser degree, ablate bone marrow, depending on dosage, but patients do not require transplantation.

When first suggested by Burns et al. as a treatment for MS in 1995, aHSCT was proposed to be reserved for patients with progressive disease at onset and was considered an end-stage therapeutic option [39]. Indeed, the first clinical trials included severely affected patients with progressive forms of MS, for whom the protocol of high-dose conditioning followed by aHSCT demonstrated encouraging results [40, 41]. Subsequent clinical trials and observational or retrospective studies that assessed the efficacy of aHSCT using EDSS score, of which there are to the authors’ knowledge approximately 46, have included low-, intermediate- and high-intensity conditioning regimens. Initially, cohorts of patients with progressive forms of MS were included, and soon after mixed cohorts that included those with relapsing forms, with more recently just or mostly RRMS patients being included. Over time, it has become clearer that perhaps the patients who benefit most from aHSCT are those that have RRMS, a lower EDSS score and a shorter disease course—younger age likely also contributes, but all trials assessed young (a median/mean of < 45 years old) patients and there is, therefore, little evidence to support the safety and efficacy of aHSCT in older patients with MS. Despite the accumulative high-quality clinical research over the past 20 years, the heterogenous transplantation regimens, patient populations and description of outcomes do not allow for a robustly evidenced consensus regarding how, when and whom to treat, as well as hinder our understanding of the mechanism of action of aHSCT.

This review, therefore, aims to provide a clear overview of clinical trials treating MS patients with aHSCT, stratified based on conditioning regimen intensity as per the EBMT [38] and the type of study, with the applicable Oxford Centre for Evidence-Based Medicine (OCEBM) Level of Evidence. In addition, the occurrence of late-onset autoimmune disease following aHSCT will be explored. Of note, the reporting of EDSS score has been used most often to compare outcomes and describe study efficacy in this review as, following screening of the articles, it became clear that EDSS was almost always given as an outcome in clinical trials as well as a baseline parameter, thereby serving as a common denominator among otherwise highly heterogeneous articles.

**Overview of aHSCT studies**

A total of 2574 patients have been included in either clinical trials or retrospective or observational studies with EDSS as a reported outcome; however, considering, for example, that some patients described in the observational studies likely cross over with those described in the clinical trials, that value may well be an overestimate. 831 (32.3%) patients have been included in 28 clinical trials and 1743 (67.7%) in 18 retrospective or observational studies. As the mean or median age (mAge), duration of MS (mDMS), EDSS at baseline (mbEDSS) and follow-up (mFU) were given variably as either median or mean values among the studies, it is not possible to evaluate the overall median for these data points. These parameters have, however, been listed in Tables 1, 2, 3, 4, 5 and 6, which provide an overview of the studies grouped according to conditioning regimen and study type. The details of each conditioning regimen are given in Supplementary Data 1, Conditioning Regimens. In addition, outcome reporting was heterogeneous with, for example, progression-free survival (PFS) being the most frequently reported measure but given only by 24 (52.2%) of studies. Duration of follow-up was also varied, with a range of 6 months to 11.3 years, making comparison of outcomes challenging.

**Clinical trials: myeloablative**

**Non-randomised, uncontrolled clinical trials**

The majority of clinical trials are non-randomised and uncontrolled in this field of research, of which 14 used myeloablative conditioning regimens of either high- (4 trials, [42–45]) or intermediate-intensity (10 trials, [40, 46–54]) regimens (Table 1). All trials were phase I, II or I/II.

The high-intensity regimens mostly included SPMS patients with few RRMS, with the 2016 Atkins et al. trial as the exception, including 50% RRMS and 50% SPMS [45]. Patients who were included generally had active disease with progression within the year prior to aHSCT and had trialled at least 1 DMT. The mbEDSS ranged from 6 to 7. Interestingly, Atkins’ trial including the most RRMS patients also demonstrated the best outcomes of all high-intensity regimens in terms of EDSS at last FU. Specifically, stable disease was observed in 70% of patients, whereas the 2003 trial by Nash et al., 2003 trial by Burt et al. and 2006 trial by Samijn et al. described 54%, 19% and 21% of patients being stable at last follow-up, respectively [42–44]. With regard to improvement in EDSS, the highest proportion of patients improved at last follow-up was reported by Samijn et al. at 14%, then Nash et al. at 8% and Burt et al. at 4%. However, each study had a different mFU duration (Table 1). Nash et al. observed patients for the longest time, with a mFU of 12 years. These data demonstrate that for predominantly SPMS-containing patient cohorts, with significant proportions of PRMS and PPMS patients in the Nash et al. and Burt et al. trials, respectively, long-term improvement...
Table 1  Non-randomised, uncontrolled clinical trials. OCEBM level of evidence 2b

| Authors            | Year published | Country   | Phase | No. of patients | Age  | MS duration (y) | Type of MS          | EDSS (baseline) | Follow-up (y) | EDSS (final) | PFS (y) | Death due to aHSCT |
|--------------------|----------------|-----------|-------|----------------|------|----------------|---------------------|----------------|---------------|--------------|---------|-------------------|
| Intermediate-intensity, myeloablative |
| Nash et al         | 2017           | USA       | II    | 24             | 37   | 4.9            | RRMS                | 4.5            | 5.2           | 62% improved, 21% stable | 5 y: 91.3% | 0                 |
| Moore et al        | 2019           | Australia | II    | 35             | 37   | 6.9            | RRMS (57%), SPMS (43%) | 6              | 3             | 44% improved | 3 y: 88% (RRMS) | 0                 |
| Shevchenko et al   | 2012           | Russia    | II    | 95             | 34.5 | –              | RRMS (44%), SPMS (37%), PPMS (16%), PRMS (3%) | 3.5            | 3.8           | 80% improved or stable | 5 y: 92% early; 5 y: 73% conventional/salvage | 0                 |
| Saiz et al         | 2004           | Spain     | I     | 14             | 32.3 | 14.9           | RRMS (36%), SPMS (64%) | 6              | 3             | 28% improved, 57% stable | 3 y: 85.7% | 0                 |
| Saccardi et al     | 2005           | Italy     | II    | 19             | 36   | 12            | SPMS (79%), RRMS (21%) | 6.5            | 3             | 58% improved, 26% stable | 6 y: 95% | 0                 |
| Capello et al      | 2005           | Italy     | II    | 21             | 36   | 12            | SPMS (81%), RRMS (19%) | 6.5            | 2             | 95% improved or stable | 0                  | 0                 |
| Hamerschalk et al  | 2010           | Brazil    | I     | 20             | 42   | 5.3           | SPMS (86.7%), PPMS (9.5%), RRMS (4.8%) | 6.5            | 3             | 44.4% worse | 0                  | 3                 |
| Kozák et al        | 2001           | Czech Republic | I | 10            | 39   | –              | SPMS                      | 6.5            | 0.8           | 40% improved, 50% stable | 0                  | 0                 |
| Mancardi et al     | 2001           | Italy     | I     | 10             | 35.5 | 12            | SPMS                      | 6.5            | 1.3           | 100% improved or stable | 0                  | 0                 |
| Fassas et al       | 1997           | Greece    | I/II  | 15             | –    | 10            | PMS                       | 6              | 0.5           | 47% improved, 47% stable | 0                  | 0                 |
| High intensity     |
| Atkins et al       | 2016           | Canada    | II    | 24             | 34   | 5.8            | RRMS (50%), SPMS (50%) | –              | 6.7           | 70% stable | –              | 1                  |
| Nash et al         | 2003           | USA       | I     | 26             | 41   | 7             | SPMS (65%), PPMS (31%), RRMS (4%) | 7              | 12            | 8% improved, 54% stable | –              | 1                 |
| Samijn et al       | 2006           | The Netherlands | I | 14            | 35   | 5              | SPMS                      | 6              | 3             | 14% improved, 21% stable | –              | 0                 |
| Burt et al         | 2003           | USA       | I/I   | 21             | 40   | 7             | SPMS (66%), PRMS (28%), RRMS (4%) | 7              | 2.6 (EDSS > 6), 1 (EDSS < 6) | 4% improved, 19% stable | –              | 0                 |
### Table 2  Randomised, controlled clinical trials. OCEBM level of evidence 1b

| Authors       | Year published | Country                  | Phase | No. of patients | Age  | MS duration (y) | Type of MS          | EDSS (baseline) | Follow-up (y) | EDSS (final) | PFS (y) | Death due to aHSCT |
|---------------|----------------|--------------------------|-------|-----------------|------|-----------------|---------------------|-----------------|---------------|--------------|---------|---------------------|
| Mancardi et al | 2015           | Italy and Spain          | II    | 9 (21 total)    | 36   | 10.5            | SPMS (78%), RRMS (22%) | 6.5             | 4             | 57% progressed | –       | 0                   |
| Burt et al    | 2019           | USA, UK, Sweden, Brazil  | III   | 55 (110 total)  | 35.6 | 4.7             | RRMS                | 3               | 2             | 94.5% stable or improved | Too few events | 0 |

### Table 3  Non-randomised, controlled clinical trial. OCEBM level of evidence 2b

| Authors       | Year published | Country | Phase | No. of Patients | Age  | MS Duration (y) | Type of MS | EDSS (baseline) | Follow-up (y) | EDSS (final) | PFS (y) | Death due to aHSCT |
|---------------|----------------|---------|-------|-----------------|------|-----------------|------------|-----------------|---------------|--------------|---------|---------------------|
| Mariotti et al | 2019           | Italy   | II    | 11 (52 total)   | 35   | 10.5            | RRMS       | 3.25            | 3             | 44.4% improved | –       | 0                   |
Table 4  Non-Randomised, uncontrolled clinical trials. OCEBM level of evidence 2b

| Authors          | Year published | Country     | Phase | No. of patients | Age (y) | MS duration (y) | Type of MS | EDSS (baseline) | Follow-up (y) | EDSS (final)  | PFS (y) | Death due to aHSCT |
|------------------|----------------|-------------|-------|-----------------|---------|-----------------|------------|----------------|---------------|---------------|---------|-------------------|
| **Intermediate-intensity, lymphoablative** | | | | | | | | | | | | |
| Burt et al 2009  | USA            | I/II        | 21    | 33              | 5       | RRMS            | 3.1        | 3.1            | 90.5% improved, 9.5% stable | 3 y: 100% | 0               |
| Curro et al 2015 | Italy          | I           | 7     | 28              | 6.5     | RRMS            | 6          | 5              | 14% improved, 29% stable | –         | 0               |
| Giedraitiene et al 2020 | Lithuania | II  | 24    | 37.8            | 8.6     | RRMS            | 5.9        | 2              | 23.1% improved, 76.9% stable | –         | 0               |
| Hannerschalk et al 2010 | Brazil | I  | 21    | 41              | 4.7     | SPMS (75%), RRMS (15%), PPMS (10%) | 6.5        | 2              | 30% worse | –         | 0               |
| Cull et al 2017  | Australia      | I           | 13    | 44.8            | 12.5    | SPMS (77%), PPMS (23%) | 7.2        | 3              | 69% stable | 3 y: 69% | 0               |
| Dayama et al 2020 | India         | I/II        | 20    | 31.5            | –       | SPMS (55%), RRMS (45%) | 5.5        | 0.7            | 36.8% improved (66.6% of RRMS cohort) | 1 y: 100% | 0               |
| de Paula et al 2015 | Brazil     | I           | 16    | 38              | 8.8     | SPMS (50%), RRMS (37.5%), PPMS (12.5%) | 5          | 2              | 75% improved or stable | –         | 0               |
| **Low intensity** | | | | | | | | | | | | |
| Su et al 2006    | China          | I           | 15    | 36              | 3       | SPMS            | 6          | 2.9            | 40% improved, 27% stable | 4.1 y: 63.8% | 0               |
| Xu et al 2006    | China          | I           | 22    | 35.5            | 3       | SPMS            | 6          | 3.3            | 59% improved, 18% stable | 4.9 y: 77% | 0               |
| Authors      | Year published | Country      | Regimen                                      | No. of patients | Age  | MS duration (y) | Type of MS                      | EDSS (baseline) | Follow-up (y) | EDSS (final)       | PFS (y) | Death due to aHSCT |
|--------------|----------------|--------------|----------------------------------------------|----------------|------|----------------|---------------------------------|----------------|--------------|-------------------|---------|-------------------|
| Clinical trials (Phase I and I/II) |                |              |                                              |                |      |                |                                 |                |              |                   |         |                   |
| Ni et al     | 2006           | China        | High (4.8%), intermediate myeloablative (95.2%) | 21             | 37   | 3.8            | SPMS (89%), PPMS (11%)           | 7.5            | 3.5          | 44% improved, 44% stable | 3.5 y: 75% | 0                 |
| Fassas et al | 2002           | Multi-centre | High (24%), intermediate myeloablative (47%), intermediate lymphoablative (13%), low (16%) | 85             | 39   | 7              | SPMS (70%), PPMS (26%), RRMS (4%) | 6.5            | 1.3          | 14% improved       | 3 y: 63% (PPMS), (78%) SPMS/RRMS | 5       |
| Fassas et al | 2011           | Greece       | High (28.6%), intermediate myeloablative (42.9%), low (28.6%) | 35             | 40   | 7              | SPMS (54%), PMS (11%), PPMS (31%), RRMS (2%) | 6              | 11.3         | 6% improved, 20% stable | 15 y: 25% | 2                 |
| Observational and retrospective studies |                |              |                                              |                |      |                |                                 |                |              |                   |         |                   |
| Frau et al   | 2018           | Italy        | Intermediate lymphoablative (77.8%), low (22%) | 9              | 38   | 10             | 56% RRMS, 22% SPMS, 11% PPMS, 11% PRMS | 5.3            | 11           | 22% improved, 22% stable | –         | 0                 |
| Muraro et al | 2017           | Multi-centre | High (18.8%), intermediate myeloablative (38.8%), intermediate lymphoablative (22.8%), low (19.6%) | 281            | 37   | 6.8            | SPMS and PPMS (77.5%), RRMS and PRMS (22.4%) | 6.5            | 6.6          | Possible reduction in disability accrual in RRMS group | 5 y: 45% (RRMS 75%) | 8       |
| Boffa et al  | 2021           | Italy        | Intermediate myeloablative (74.8%), intermediate lymphoablative (12.9%), low (12.5%) | 210            | 34.8 | 11             | RRMS (58%), SPMS (41%), PPMS (1%) | 6              | 6.2          | Mean EDSS change per year = 0.09 (RRMS). Stable in PMS | –         | 3                 |
Table 5 (continued)

| Authors      | Year published | Country  | Regimen                                                                 | No. of patients | Age (y) | MS duration (y) | Type of MS | EDSS (baseline) | Follow-up (y) | EDSS (final) | PFS (y) | Death due to aHSCT |
|--------------|----------------|----------|-------------------------------------------------------------------------|-----------------|---------|-----------------|-------------|-----------------|--------------|--------------|---------|---------------------|
| Burman et al | 2014           | Sweden   | Intermediate myeloablative (81.3%), intermediate lymphoablative (18.8%) | 48              | 31      | 6.3             | 83% RRMS, 10% SPMS, 4% PPMS, 2% PRMS | 6               | 4            | 2 y: 3 (5.5) (RRMS), 2 y: 6.5 (6.5) (PRMS) | 5 y: 77% | 0                   |
| Tolf et al   | 2019           | Sweden   | Intermediate myeloablative (90%), intermediate lymphoablative (10%)     | 10              | 27      | 2.3             | RRMS        | 6.5             | 10           | 100% improved | –        | 0                   |
| Das et al    | 2021           | Multi-centre | Intermediate myeloablative (?), intermediate lymphoablative (?) | 20              | –       | 5               | “Aggressive” MS | –               | 2.5          | 65% stable, 25% improved | –        | 0                   |
| Nicholas et al | 2021           | UK       | Intermediate myeloablative (0.8%), intermediate lymphoablative (99.2%) | 120             | 42.3    | 8.9             | 48% RRMS, 52% PPMS or SPMS | 6               | 1.75        | 65% stable | 4 y: 65% | 3                   |
### Table 6  Retrospective and observational studies. OCEBM level of evidence 2b

| Authors              | Year published | Country          | No. of patients | Age (y) | MS duration (y) | Type of MS                   | EDSS (baseline) | Follow-up (y) | EDSS (final)     | PFS (y) | Death due to aHSCT |
|----------------------|----------------|------------------|-----------------|---------|-----------------|------------------------------|----------------|---------------|-------------------|---------|-------------------|
| Intermediate-intensity, myeloablative |                 |                  |                 |         |                 |                              |                 |               |                   |         |                   |
| Casanova et al       | 2017           | Spain            | 31              | 37      | 9.5             | 71% RRMS, 29% SPMS           | 5               | 8.4           | 60% improved, 40% stable (RRMS); 78% progression (SPMS) | 12 y: 100% (RRMS) | 0                  |
| Häußler et al        | 2021           | Germany, France  | 19              | 35.1    | 5.4             | 63% RRMS, 16% PPMS, 21% SPMS | 4.5             | 4.9           | 35.7% improved | –       | 0                  |
| Mancardi et al       | 2012           | Italy            | 74              | 35.7    | 11.2            | 45% RRMS, 55% SPMS           | 6.5             | 4             | > 7 y: 17% stable, 27% improved | 5 y: 66% | 2                  |
| Krasulova et al      | 2010           | Czech Republic   | 26              | 33      | 7               | 42% RRMS, 58% SPMS           | 6               | 5.5           | –                 | 3 y: 84.4% (RRMS), 3 y: 60% (SPMS) | 0                  |
| Mariottini et al     | 2021           | Italy            | 26              | 37      | 9               | SPMS                         | 6               | 8.3           | 38% worse | 10 y: 30% | 0                  |
| Mariottini et al     | 2022           | Italy            | 31 (93 total)   | 39.3    | 13.7            | SPMS                         | 5.9             | 8.3           | 55% worse | 5 y: 70% | 0                  |
| Intermediate-intensity, lymphoablative |                 |                  |                 |         |                 |                              |                 |               |                   |         |                   |
| Zhukovsky et al      | 2021           | Sweden           | 145             | 30      | 6.4             | RRMS                         | 3               | 2.8           | Improved by 1 on average | –       | 0                  |
| Kvistad et al        | 2020           | Norway           | 30              | 30.8    | 5.2             | RRMS                         | 3               | 2.2           | 43% improved, 50% stable | –       | 0                  |
| Burt et al           | 2015           | USA              | 151             | 36      | 5.1             | RRMS                         | 4               | 2             | 52% improved | 4 y: 87% | 0                  |
| Burt et al           | 2021           | USA              | 507             | 37      | 6               | 82% RRMS, 18% newly diagnosed SPMS | 4               | 3             | 5 y: 2.19 (3.87) (RRMS), 4 y: 4.72 (5.09) (SPMS) | 4 y: 95% (RRMS), 4 y: 66% (SPMS) | 1                  |
| Low intensity        |                 |                  |                 |         |                 |                              |                 |               |                   |         |                   |
| Comini-Frota et al   | 2019           | Brazil           | 5               | 29      | 11              | RRMS                         | 5.7             | 9             | 80% improved, 20% stable | –       | 0                  |
or stability of EDSS is possible. Heterogeneous reporting, patient cohorts and mFU as well as these trials being non-randomised and uncontrolled with a total of 85 patients included does not, although demonstrating promising outcomes in some cases, provide a strong evidence base for offering patients with progressive forms of MS high-intensity aHSCT, particularly given that this type of transplant is associated with the highest occurrence of death (see “Adverse events, mortality and autoimmune disease”). Data for patients with RRMS for this conditioning regimen are slighter still with very little evidence available to support offering these patients high-intensity conditioning regimens.

Non-randomised, uncontrolled trials including intermediate-intensity myeloablative conditioning regimens also mostly included patients with progressive forms of MS, namely SPMS (Table 1). Mancardi et al. included a cohort of 10 patients with SPMS, 100% of whom were improved or stable with regard to EDSS at a mFU of 1.3 years [54]. These patients had a mDMS of 12 years, mAge of 35.5 years and mbEDSS of 6.5, which would imply that this cohort is very much burdened by disease and so the impressive findings are encouraging, although the mFU is short. As demonstrated in Table 1, the mFU was quite short for all clinical trials, save for the 2017 Nash et al. trial, which included RRMS patients only and provided strikingly promising data, with the longest mFU of 5.2 years [46]. For these patients, a 5-year PFS of 91.3%, 62% improvement in EDSS and a stable EDSS score in 21% was observed at last follow-up. Long-term PFS for a smaller proportion of the initial patient cohort was given by Shevchenko et al. and Saccardi et al. (Table 1) [48, 50]. Regarding the former, PFS was 92% at 5 years for patients who had received early transplantation and 73% for those who received aHSCT on conventional or salvage grounds. This is one of few trials to demonstrate that the hit hard and early strategy does provide better outcomes, with a cohort including 44% RRMS, 37% SPMS, 16% PPMS and 3% PRMS patients, and with a mFU of 3.8 years. Saccardi et al. noted a 6-year PFS of 95% for a cohort of predominantly SPMS patients, as well as encouraging EDSS outcomes at last follow-up with 84% improved or stable. These 10 trials provide information on a total of 224 patients, with encouraging PFS rates and EDSS scores at last follow-up following intermediate-intensity myeloablative conditioning for a diverse population of MS patients.

Randomised, controlled clinical trials

The only randomised, controlled trial for myeloablative aHSCT, performed by Mancardi et al., was of intermediate intensity, had mitoxantrone as the comparison arm, and included a total of 21 patients, of whom 9 underwent a transplantation [55] (Table 2). The majority of patients had SPMS and, after a mFU of 4 years, 57% of patients experienced worsened disability. Patients who received aHSCT did have significantly fewer (79%) MRI lesions compared to mitoxantrone and a reduced annualised relapse rate, but with no difference in disability progression between groups. Few conclusions may be drawn from such a small cohort, despite an OCEBM Level of Evidence of 1b.

Non-randomised, controlled clinical trials

Mariottini et al. designed a non-randomised, controlled trial to establish the efficacy of aHSCT following cessation of natalizumab in 52 RRMS patients, of whom 11 underwent transplantation with an intermediate-intensity regimen [56] (Table 3). The remaining patients received a DMT. After a mFU of 3 years, 44.4% of patients had an improved EDSS score and NEDA was reported in 54.4% compared to 11.5% of the control group. Again, although encouraging, it is challenging to confidently base treatment decisions on such a small cohort of patients.

Clinical trials: lymphoablative

Non-randomised, uncontrolled clinical trials

Nine of the non-randomised, uncontrolled trials included low-intensity (two trials, [57, 58]) or intermediate-intensity lymphoablative regimens (seven trials, [52, 59–64]) (Table 4). All trials were phase I, II or I/II.

Again, the majority of trials included patients with SPMS, although three included RRMS patients only. Of these three, which all used intermediate-intensity regimens, the 2009 trial by Burt et al. observed a 90.5% improvement in EDSS at last follow-up, mFU was 3.1 years, with 9.5% of patients remaining stable [59]. PFS was 100% and NEDA 62% at 3 years. The 21 patients in this cohort had a mAge of 33, mbEDSS of 3.1, mDMS of 5 years and had experienced treatment failure on DMT. Further significant improvements were seen in neurological rating scale score, the paced auditory serial addition test, the 25-foot walk test and Short Form-36 score (SF-36). In contrast, the 2 other studies including RRMS patients only, for whom DMT had also not been effective, were by Curro et al. and Giedraitiene et al. and observed EDSS improvements of 14% (29% were stable) and 23% (77% were stable), respectively, but with an almost twice as high mbEDSS compared to the Burt et al. cohort [60, 61]. Interestingly, Giedraitiene et al. found that patients with a lower baseline EDSS had better outcomes. These data add evidential weight to the EBMT guidelines that patients with a lower EDSS score are the optimal candidates for aHSCT but included only small patient cohorts. The other three intermediate-intensity regimen trials included mainly SPMS patients, with Cull et al.
providing the longest mFU of 3 years and describing disease stability in 69% of patients [62]. Although Dayama et al. also reported encouraging results, the mFU was 0.7 years, and therefore too short to provide meaningful data [63]. The intermediate-intensity regimens were assessed in trials that enrolled a total of 106 patients, with some encouraging data and an interesting suggestion that lower EDSS score correlates with improved outcomes.

The two low-intensity regimens included in this section used chemotherapy-only conditioning regimens, i.e. did not use ATG, and were, therefore, classified as low intensity as per the EBMT guidelines [38, 57, 58]. However, both trials used the BEAM regimen, which is often considered an intermediate-intensity regimen. Both studies report encouraging results for SPMS only patient cohorts, with Su et al. observing a 4.1-year PFS of 63.8% and Xu et al. a 4.9-year PFS of 77% (Table 4). Most trials use ATG and it is noteworthy that these two trials reporting encouraging outcomes do not.

Randomised, controlled clinical trials

The 2019 Burt et al. randomised, controlled trial using an intermediate-intensity lymphoablative regimen included RRMS patients only, a total of 110, of whom 55 received a transplantation (Table 2) [65]. Of note, 31 patients in the DMT group crossed over to receive aHSCT due to worsening disability at 1 year. It should, however, be noted that the DMT group included a high proportion of patients treated with glatiramer acetate or the IFN-β drugs and few with higher intensity medications such as natalizumab or fingolimod. Progression occurred in 3 of the aHSCT patients and 34 of the DMT control group, with the EDSS in the aHSCT group at a mFU of 2 years stable or improved in 94.5%. NEDA at 5 years was 78.5% in the aHSCT group compared to 2.97% in the DMT group. These data quite clearly indicate better long-term outcomes for patients with RRMS receiving intermediate-intensity lymphoablative aHSCT compared to DMT, albeit the less effective DMTs, in a relatively large patient cohort.

Clinical trials: heterogeneous conditioning regimens

The three phase I or I/II trials including heterogeneous conditioning regimens and heterogeneous patient populations are difficult to critically analyse [66–68] (Table 5). Of particular interest in this cohort is the trial by Fassas et al., who was the first to perform aHSCT in patients with MS in 1997 and provides the longest mFU data of all studies (11.3 years) [67]. The 15-year PFS in this cohort was 25%, with patients that had a lower baseline EDSS demonstrating better outcomes.

Retrospective and observational studies: myeloablative

All retrospective and observational studies used intermediate-intensity myeloablative regimens [69–74] (Table 6). A remarkable 100% 12-year PFS in the RRMS cohort has been reported by Casanova et al., with the RRMS cohort demonstrating better outcomes than those with SPMS [69]. For these patients, mbEDSS was 5, mAge 37, at least 1 DMT had been trialled and the mDMS was 9.5 years. At last follow-up, mFU was 8.4 years, 60% of the patients with RRMS had improved and 40% were stable, which is in stark contrast to 77.8% of the SPMS cohort experiencing disability progression. In addition, Casanova et al. observed that poor response to aHSCT was predicted by high EDSS score at baseline. Again, demonstrating better outcomes for RRMS compared to SPMS patients is Krasulova et al., with a 3-year PFS of 84.4% and 60%, respectively. Krasulova et al. also observed better PFS outcomes in patients with disease duration of less than 5 years and patients under 35 [73]. Of note, Mancardi et al. found that a greater improvement in EDSS was associated with RRMS patients compared to those with SPMS, age below 40 and disease duration of less than 5 years [72]. Mariottini et al. report a 10-year PFS and NEDA of 30% for their SPMS cohort, further demonstrating that very long-term outcomes are better for RRMS patients [71]. Of note, Häußler et al. reported a 10-year NEDA of 62% following aHSCT and demonstrated that patients receiving aHSCT had better outcomes than those receiving ALEM [70]. Mariottini et al. compared the BEAM + ATG regimen for aHSCT with CY 0.75 g/m2 BSA given monthly for the first year of treatment, then every second month in the second year and quarterly in the third year [74]. aHSCT was found to be more effective at preventing relapse than CY but the effect on long-term disability progression was similar between groups.

Retrospective and observational studies: lymphoablative

Six studies included lymphoablative regimens, with one being of low [75] and four of intermediate intensity [76–79]—all these studies included mainly RRMS patients (Table 6). Of these 4, and indeed of the entire 46 studies described in this review, the largest patient cohort was provided by Burt et al. and reported recently in this journal, which included 507 patients with RRMS (82%) and newly
diagnosed SPMS (18%) [79]. In keeping with the findings from the myeloablative retrospective and observational studies, Burt et al. described a PFS at 4 years of 95% for patients with RRMS and 66% for those with SPMS. At 5 years, mEDSS had improved to 2.19 from 3.87 in the RRMS patients and at 4 years to 4.72 from 5.09 in the SPMS patients. Of note, Zhukovsky et al. demonstrated in their cohort of 145 RRMS patients that EDSS score improved by 1 on average with a mFU of 2.8 years, corroborating with the findings of Burt et al.’s 2021 data [76]. Again, similar to the findings of the myeloablative regimens, namely Häußler et al. [70], Zhukovsky et al. reported superiority of aHSCT compared to ALEM. The data for RRMS patients receiving intermediate-intensity lymphoablative aHSCT reflects outcomes from a remarkable 833 patients and is similar across studies, providing supportive evidence for this regimen in patients with RRMS. The low-intensity regimen also demonstrated very encouraging data but included only 5 patients [75].

Retrospective and observational studies: heterogeneous conditioning regimens

Retrospective and observational studies containing data with heterogeneous regimens are included in Table 5 [80–86]. Muraro et al. analysed data from 281 patients and again demonstrated better PFS in RRMS patients and in patients with a lower EDSS score at baseline [82]. In addition, Muraro et al. found that younger age and fewer prior immunotherapies were associated with better outcomes. Boffa et al. included 210 patients and observed a mean EDSS change per year of -0.09 in the RRMS cohort compared to EDSS being stable in the progressive MS cohort [80], which was similar to Burman et al., who found that at 2 years the RRMS cohort mEDSS had improved to 3 from 5.5 and in the PRMS cohort had remained stable 6.5 [84]. Also of note in this group of studies is that Tolf et al. reported 100% of the 10 patients with RRMS had improved EDSS scores after a mFU of 10 years [85]. Although heterogenous, 698 patients were included and results from this large cohort reflect the data from the other retrospective and observational studies.

Key points from the clinical trial data and EBMT guidance

High-quality evidence in the form of randomised, controlled trials is needed to compare the efficacy of aHSCT to the currently available highly effective DMTs and thereby draw confident conclusions regarding the risk vs. benefit of transplantation in MS. However, the clinical trials discussed in this review provide critical guidance regarding patient selection and transplantation protocol, with further advice for experienced centres considering aHSCT also provided by the EBMT [38]. Data from the trials included in this review demonstrate that younger age, shorter duration of disease, relapsing–remitting disease course and lower baseline EDSS have better outcomes. The EBMT advise that aHSCT may be considered for patients aged 45 or younger with highly active RRMS, an EDSS of 5.5 or less and a duration of disease of 10 years or less, who have failed at least one first-line DMT [38]. In addition, they suggest that patients with aggressive MS, i.e. with a rapidly accelerated disease course, may be considered for aHSCT prior to completion of the full course of a first-line DMT [38]. Following patient selection, an extensive pre-aHSCT evaluation of fitness for transplantation including echocardiography, electrocardiogram, pulmonary function testing, blood testing including an infection screen, and psychological evaluation must occur. In addition to this, counselling of patients regarding the risks of transplantation is required, particularly death, serious adverse events, infection, autoimmune disease, and infertility. Patients who meet the inclusion criteria may, therefore, be excluded following evaluation of fitness for transplantation. With regard to transplantation protocol, the data from this review suggest that high-intensity conditioning is associated with an increased occurrence of death without obvious benefit to efficacy. Low-intensity regimens were rarely used. Conditioning using CY + ATG and BEAM + ATG appear to be the most widely used, with both demonstrating promising efficacy and both suggested as the most evidenced options by the EBMT [38]. CY + ATG appears to offer a better safety profile from the data in this review, particularly with Burt et al.’s real-world cohort of 507 patients providing encouraging outcomes and safety data. It should also be noted that the promise of aHSCT for patients with SPMS remains to be fully clarified, with the EBMT suggesting that patients with active inflammation and clear disability progression may be the best candidates, but this should be considered in the context of a clinical trial [38]. In support of this is the very recent retrospective study by Mariotti et al. that compared SPMS patients treated with aHSCT (using BEAM + ATG) to those treated with CY alone, i.e. immunosuppression only, and demonstrated that aHSCT was far superior to CY at suppressing inflammation, e.g. reducing relapses, but had a minimal effect on disability progression [74].
Adverse events, mortality and autoimmune disease

The expected side effects of stem cell transplantation were noted in most studies, in which adverse events were described, e.g. viral reactivation, bacterial infection, and febrile neutropenia. Of particular interest is the reporting of death and the occurrence of autoimmune disease, as these outcomes are perhaps less expected than the more common side effects and relevant to the discussions had with patients prior to aHSCT. In addition, this section will discuss the potential for neurotoxicity and secondary malignancy using these agents, as well as implications on fertility, vaccination, and immunity. It should be noted that both the very earliest and the most recent trials have been included in this review. The treatment-associated mortality of aHSCT has improved in recent years [35], which should be kept in mind when considering these outcomes. Of interest, Mancardi et al. describe that, in Europe, the mortality due to aHSCT was 7.3% between 1995 and 2000 and 1.3% between 2001 and 2007 [87].

Death

The percentage of total patients who underwent transplantation and died as a consequence, with deaths related to conditioning regimen, was 2.4% following a high-intensity regimen (2 deaths, 85 patients), 1% following myeloablative intermediate-intensity conditioning (5 deaths, 491 patients), 0.1% following lymphoablative intermediate-intensity conditioning (1 death, 1065 patients) and 0% following low-intensity conditioning (0 deaths, 42 patients). The two deaths following high-intensity transplant were due to massive hepatic necrosis (conditioning regimen: 14.9 mg/kg busulfan) [45] and Epstein–Barr virus (EBV)-related post-transplantation lymphoproliferative disorder (associated with a change from horse-derived to rabbit-derived ATG) [42]. Following myeloablative intermediate-intensity conditioning, five deaths were due to cardiac toxicity in one patient (1), sepsis (1) and alveolar haemorrhage (1) [52], engraftment failure, subsequent Actinomyces spp. infection and disseminated intravascular coagulation (1) [72] and encephalopathy of unknown aetiology (1), with all deaths following BEAM + ATG [72]. The single death in the intermediate-intensity lymphoablative cohort was due to hospital-acquired legionella pneumonia [79]. It is worth noting that in their CY control group, Mariottini et al. described one death due to pneumonia 17 years following treatment and one death due to intracerebral haemorrhage with thrombocytopenia following splenectomy for a splenic infarct 8 years following treatment [74].

In the three clinical trial cohorts of patients receiving heterogenous conditioning regimens, seven transplant-related deaths were reported by Fassas et al., of which five occurred during the clinical trial for which results were published in 2002 and two in the long-term follow-up report of the 1995 clinical trial, published in 2011 [66–68]. The five deaths reported in 2002 were due to cardiac toxicity (1, BEAM only regimen), cerebral aspergillosis (1, BEAM + ATG), septicaemia (1, BEAM + ATG), influenza pneumonia (1, busulfan (Bu) + CY + ATG) and postoperative pneumococcal sepsis (1, Bu + CY + ATG), the latter of which occurring 19 months after transplant. Including these deaths in the mortality data increases the percentage of total patients dying as a consequence of high-intensity conditioning to 3.8% (4 deaths, 105 patients), myeloablative, intermediate-intensity conditioning to 1.4% (7 deaths, 501 patients), and low-intensity conditioning to 1.8% (1 death, 56 patients). The two deaths reported in 2011 were due to pulmonary haemorrhage associated with post-transplant-onset acquired haemophilia A (1) and aspergillosis (1), occurring in the BEAM cohort and the Bu cohort, although it is unclear which death was associated with which conditioning regimen. Of note, Ni et al. reported no deaths associated with transplantation but acknowledged one patient dying of severe pneumonia at 4.5 months following transplant and a further patient suffering from varicella-zoster hepatitis at 15 months post-transplant in a cohort of 21 patients receiving either a high- or intermediate-intensity conditioning regimen [68].

Muraro et al. analysed factors associated with worse overall survival in a multi-centre, heterogenous cohort of patients included in an observational study, within which 8 deaths were reported, and found that higher baseline EDSS was significantly associated with a higher risk of death over time [82]. Combined with the evidence that suggests patients with a lower EDSS score have better outcomes in terms of disease progression, this further supports the patient selection parameters suggested by the EBMT [38, 82]. In addition, Muraro et al. observed that, among the patients who died, progressive MS and high-intensity conditioning regimens were overrepresented compared to the frequency of these factors in the entire cohort [82]. In this study, we also found that high-intensity conditioning regimens were associated with the highest percentage of patient deaths, which is unsurprising given that this treatment includes aggressive myeloablative agents. Boffa et al. reported the deaths already reported by Mancardi et al. but considered the death due to pulmonary thromboembolism followed by syncope and head trauma 56 days after AHSCT as transplantation-related, which Mancardi et al. had reported, following review by an independent committee, as not related to transplantation [72]. Nicholas et al. also reported three deaths in a cohort who received heterogenous regimens, which were due to
cardiac arrest secondary to recent pulmonary oedema the
day before transplantation (1), cardiac arrest secondary
to electrolyte abnormalities (1), and acute respiratory dis-
tress syndrome (ARDS) secondary to a chest infection and
sepsis (1) [86]. Regarding potentially life-threatening side
effects unrelated to infection, Giedraitiene et al. reported a
case of ARDS during the administration of conditioning
with CY + ATG that resolved with glucocorticoid therapy
[61] and Mancardi et al. reported life-threatening dyspnoea,
bradycardia, and hypoxemia secondary to ATG [55]. Of
note, Ni et al. reported one allergic reaction to CY and a
further allergic reaction to ATG in another patient.

Neurotoxicity

Interestingly, neurotoxicity was rarely reported in the trials
considered by this review but is often reported in the con-
text of stem cell transplantation more generally, and agents
used in the BEAM regimen, for example, certainly have the
potential to be neurotoxic [88–91]. Perhaps this is due to the
aHSCT regimens often used in MS, and those recommended
by the EBMT [38], using less potent dosages of ablative
agents for a relatively short duration as a part of “interme-
diate-intensity” regimens, as complete myeloablation is not
the priority. Transient neurological deterioration was, how-
ever, described in five patients was reported by Ni et al.,
who used both a high-intensity and intermediate-intensity
regimen in SPMS and PPMS patients. The encephalopathy-
associated death reported by Mancardi et al. is perhaps also
of relevance in this context, although no definite cause was
reported [72].

Secondary malignancy

Regarding the risk of secondary malignancy in MS patients
undergoing aHSCT, conclusive evidence has not been pro-
vided by these trials and further long-term follow-up data
are required. Particularly with CY, which has been associ-
ated with bladder cancer and haematological malignancies
[92]. In the real-world Burt et al. cohort of 507 patients who
received CY, the authors specifically mention no incidence
of bladder cancer, myelodysplastic syndrome (MDS) or leu-
kaemia and report one case of death secondary to T cell
lymphoma 10 years following aHSCT, as well as one death
due to colon cancer 3 years following aHSCT [79]. Other
reports of secondary malignancy were reported by five stud-
ies. Casanova et al. reported two cases of breast cancer and
one case of cervical intraepithelial neoplasia grade 2 follow-

ing BEAM + ATG [69], Mariottini et al. reported a case of
MDS 12 years after transplantation with CY + azathioprine
[71], Samjin et al. also described a patient who developed
MDS and a further patient who developed (EBV)-related
post-transplantation lymphoproliferative disorder following

TBI + CY + ATG, who was effectively treated with rituxi-
mab [44], and Fassas et al. reported a case of prostate cancer
12 years after transplantation in the cohort who received
heterogenous conditioning regimens [67]. Mariottini et al.
reported one case of myeloproliferative disorder 12 years
following aHSCT with BEAM + ATG [74]. Interestingly, the
authors also reported Hodgkin lymphoma in one patient at
month 10 and renal cancer in one patient at year 15 follow-

ing treatment in the CY comparison group.

Infertility

Despite this being a highly relevant side effect of the agents
used in these conditioning regimens, fertility outcomes and
fertility-conserving measures were rarely mentioned by the
studies. Kvistad et al. offered all men and women below 35
in their cohort treated with CY + ATG fertility-conserving
treatment and describe 43% of women having persistent
symptoms of ovarian failure following transplantation, of
which 60% had this confirmed on further diagnostic test-
ing [77]. The oldest woman was 44 and the youngest 25.
Häußler et al. mention one case of infertility following trans-

plantation using BEAM + ATG [70]. Further evaluation of
fertility outcomes is required to understand the risk of, and
risk factors associated with, infertility for this patient cohort;
however, fertility and planning for future pregnancy should
certainly be a part of counselling for younger patients con-
sidering aHSCT.

Autoimmune disease

Reported autoimmune diseases were hyper- or hypothyroid-
ism, immune thrombocytopenic purpura (ITP), alopecia
areata, acquired haemophilia A and arthritis [56, 66, 67, 70,
74, 76, 77, 82–84]. Crohn’s disease was also reported [82,
84]. Das et al., following an intermediate-intensity either
myelo- or lymphoablative regimen in patients with aggres-
sive MS, reported the occurrence of autoimmune hypo-
or hyperthyroidism in as many as 20% of their cohort [83].
Interestingly, regarding CY + ALEM regimens, Burt et al.
reported two patients developing ITP post-ALEM in the
2009 trial [59], and in the 2015 and 2021 cohorts, Burt et al.
observed an incidence of post-transplant autoimmune dis-
ease of 22.7% and 11.5%, respectively, in the CY + ALEM
cohort vs. 6.9% and 2–3%, respectively, in the CY + ATG
cohort [79]. Häußler et al. also reported a higher number of
patients affected by autoimmune disease in their ALEM
cohort [70]. From these data, it would appear, as has been
suggested by Burt et al. and Ruck et al., that the risk of auto-
immune disease development is increased by using ALEM
in the conditioning regimen [79] [Ruck T et al. Alemtu-
zymab-induced immune phenotype and repertoire changes:
implications for secondary autoimmunity. *Brain* (2022). Ahead of publication (manuscript accepted)].

**Vaccination and immunity**

Regarding guidance for vaccination following aHSCT, a comprehensive report covering numerous aspects of immune reconstitution following aHSCT for MS was recently published on behalf of the EBMT [93]. The authors describe the loss of immunity following transplantation, as well as persistently poor immune defence against pathogens that persists for several years post-aHSCT. The EBMT guidance is, therefore, to implement a routine vaccination program 3–6 months following aHSCT, with the knowledge that, in the early post-transplantation period, vaccination response may be suboptimal [93].

**Immune reconstitution following aHSCT**

It is thought that the expansion of autoreactive T cell populations following the failure of immune tolerance mechanisms is a driving factor in MS pathogenesis [94, 95]. The restoration of self-tolerance via immune reconstitution following aHSCT is, therefore, said to be why such markedly good outcomes are observed in large cohorts of patients that, in a number of cases, persist into the long-term [96] (Fig. 1). Recently, Visweswaran et al. observed the recalibration of relevant pro-inflammatory and immunoregulatory lymphocyte subsets persisting at 36 months following transplantation [36]. The results from studies assessing immune reconstitution following aHSCT should be considered with the knowledge that each investigated a demographically different cohort of patients who had received different transplant protocols. The findings were, therefore, diverse, considering also that different immune system compartments were assessed. Those that were common among articles will be discussed in this section.

Absolute lymphopenia occurs immediately following transplantation and is reported to return to baseline levels from 6 months to 1 year post-aHSCT [47, 62, 82, 96, 97]. There is evidence of an early shift towards anti-inflammatory signalling through decreased IL-21 and 22 with increased CCL2 and CCL4 [98] as well as rapid reconstitution of NK cells post-aHSCT contributing to Th17 suppression [99], with Th17 numbers also observed to decrease by Cull et al. [62]. Visweswaran et al. observed a sustained decrease in the frequency of the Th17 subset at both 24 and 36 months, but with no change in absolute Th17 cell numbers [36]. Of note, Th17 is thought to directly participate in MS-associated neuroinflammation and damage oligodendrocytes [100]. Numerous studies report that CD4+ T cell populations do not return to baseline 2 years post-aHSCT, with altered CD4+/CD8+ T cell ratios, therefore, persisting in the long term [47, 62, 96, 97, 101]. However, Visweswaran et al. recently described the reduced CD4+/CD8+ ratio observed in their cohort beginning to normalise by 36 months post-transplantation [36]. Arruda et al. specifically demonstrated that CD4+ central memory (CD4+CM) T cell populations are ablated and both CD4+ and CD8+ effector memory (CD4+EM, CD8+EM) are preserved [96]. The authors concluded that, during the first 2 years, the peripheral T cells remaining after conditioning are the likely predominant contributors to the reconstitution of the T cell pool post-aHSCT. Muraro et al. found that CD4+EM T cells rose significantly at 6 months then declined towards baseline, whereas CD4+CM T cell populations steadily decreased during post-transplant follow-up and were significantly decreased at 2 years [102]. A significant proportion of the T cell pool occupied by the CD4+CM T cell population was then repopulated by naïve CD4+ T cells (CD4+ naïve), which has also been observed by Hakim et al. [103], that the authors suggested to evidence rejuvenation of the T cell repertoire [102]. A trend for decreased CD8+CM T cells was also observed by Muraro et al. at 2-year follow-up. However, Abrahamsson et al. did not observe a change in CD4+ naïve T cells in the CD4+ subset in their cohort of patients following lymphoablative conditioning—vs. myeloablative in the Muraro et al. cohort—and suggested that immune reconstitution is, in this context, secondary to the expansion of differentiated T cells acquiring effector cell phenotypes [97]. These data highlight that, although each conditioning regimen does demonstrate promising clinical data, the mechanisms of action may well be different and unification of future studies with regard to methodology would allow for better understanding of the mechanism of action of aHSCT in larger patient cohorts.

One of the key aspects contributing to long-term immune reconstitution has been elicited by the study of T cell receptor (TCR) diversity. Muraro et al. provided the initial data in this area of MS research and demonstrated increased clonal diversity of T cells due to de novo TCR rearrangement following aHSCT [102, 104]. The authors suggested that initial immune cell repopulation is dependent on expansion of the autologous graft, with a later (starting from > 1 year) marked increase in CD4+ T cell receptor excision circle (TREC) levels, with TREC levels being a surrogate marker for thymic activity, perhaps indicating that the later clonally expanded, more diverse populations are derived from de novo selected T cells and thymic rebound (Fig. 1). CD8+ TREC levels recovered to baseline but were not increased. Of note, thymic rebound has become an increasingly interesting concept in aHSCT research, and it may be that strategies to enhance thymic rebound would be of benefit to patients following aHSCT as a means of bolstering T cell reconstitution [105]. Harris et al. observed almost complete removal of
the pre-existing TCR repertoire following transplant, which was maintained throughout the 2 years of follow-up [101]. Interestingly, the T cell clones present in cerebral spinal fluid (CSF) prior to transplant that were not detectable in the blood did not persist after transplant, and instead > 90% of the intrathecal T cell repertoire was replaced by new clones derived from the peripheral circulation [101]. Harris et al. proposed that TCR repertoire replacement in the CSF could act as a surrogate marker for aHSCT efficacy. In addition, Amoriello et al. suggested that the evaluation of clonal persistence in memory T cell subpopulations may allow for prediction of patient outcomes following aHSCT but that this should be considered in a patient-specific, individualised manner [106].

**Monitoring the efficacy of transplant**

It was decided to use EDSS as a marker of efficacy for this review due to this parameter being the most frequently reported across studies. The EDSS also provides centres with perhaps more limited resources an inexpensive and well-evidenced monitoring tool. However, the assessment of disease activity on magnetic resonance imaging (MRI) is a highly sensitive, fundamental aspect of follow-up and should be a part of outcome reporting following aHSCT, particularly regarding evaluation of NEDA. Interestingly, MRI monitoring is not only helpful in assessing progression, but has also demonstrated, in a small number of patients, increased brain atrophy rates in the first 1 to 2 years post-transplantation—atrophy was reported to occur up to 10 times faster compared to pre-transplantation in an early report by Chen et al. [107]. The authors suggested that perhaps resolution of oedema and chemotoxicity may contribute to this finding. Inglese et al. found that progressive atrophy can occur following aHSCT independent of active inflammation on MRI, which may be related to the severe disease phenotype of transplanted patients, the aHSCT procedure, resolution of inflammation and oedema, or persistent demyelination and loss of trophic factors contributing to persistent neuronal death [108]. Few trials included in this review evaluated brain atrophy rate in relation to aHSCT. In a cohort of SPMS patients, Mariottini et al. found a slightly increased atrophy rate post-transplant that later normalised in 55% of patients [71]. Using patient data from the Samijn et al. trial [44] and again in an SPMS cohort, Rocca et al. demonstrated a median decrease in brain volume of 1.92% over the first year following aHSCT, which reduced to 1.35% in the second year then 0.69% in the third year [109]. The authors found that the number of enhancing lesions was significantly correlated with the percentage of brain volume change between baseline and month 12, but not over the second and third years. Samijn et al. reported that the rate of brain atrophy in the third year following transplantation was similar to that of patients with less aggressive forms of MS [44].

To further investigate the occurrence of brain atrophy following aHSCT, it would be of interest to assess for changes to smouldering inflammation and slowly expanding lesions, as well as serum neurofilament light chain (sNfL) levels. Of note Mariottini et al. recently analysed sNfL levels in 38 patients with RRMS or SPMS previously recruited to undergo aHSCT using a BEAM + ATG regimen and compared the data to 22 SPMS, not transplanted, patients and 19 healthy controls [110]. The authors explained that sNfL significantly decreased 24 months following transplantation, particularly in the RRMS cohort, which suggests that aHSCT can induce a durable reduction in inflammation-related axonal damage. As the reduced sNfL level at 24 months was similar to that of the SPMS control cohort, the authors suggested that this reflects resolution of recent inflammatory activity. Interestingly, Mariottini et al. also described a transient increase in sNfL 6 months following transplantation and suggested that this may be due to the toxicity of the chemotherapies or rapid suppression of inflammation causing neuronal damage, or both [110]. However, the authors state that blood samples were not collected shortly after transplant and an early increase in sNfL due to the neurotoxicity of chemotherapy could not be evaluated. Clearly, these biomarkers are of value in this context. Indeed, generally in future studies evaluating aHSCT, these more sensitive monitoring tools would be of great value to outcome data, as well as establishing whether alterations in oligoclonal band (OCB) or glial fibrillary acidic protein (GFAP) production occurs following transplantation, particularly when compared to a control group [111].

**Future clinical trials**

Currently, there are seven active studies listed on clinicaltrials.gov, of which five are recruiting. There are two clinical trials comparing aHSCT with alemtuzumab and one further comparing aHSCT with the best-available therapy (BEAT-MS). Three additional studies are assessing aHSCT for the treatment of MS. One trial is assessing the effect of faecal microbiota transplantation after aHSCT in MS. Interestingly, of these studies, AutoMS-Swe will compare the safety and efficacy between the two intermediate-intensity conditioning regimens BEAM-ATG and CY-ATG. If patients are to be treated with aHSCT at an experienced centre outside of a clinical trial, data should be sent to a patient registry, for example the EBMT Patient Registry (https://www.ebmt.org/ebmt-patient-registry).
Conclusions

There are good data available showing efficacy and safety of intermediate-intensity conditioning regimens in aHSCT for the treatment of MS. Guidelines regarding the suggested candidates and conditioning regimens for transplantation have been provided by the EBMT [38], and this review supports these recommendations. In addition, although there are minimal data available for high-intensity regimens, it does not appear that there is any benefit to choosing these more aggressive treatment options but rather that these approaches are associated with significantly more toxicity. Increased intensity of the conditioning regimen clearly does not necessarily lead to increased efficacy of aHSCT, which is supported by evidence that immune reconstitution occurs without complete myeloablation [62, 96, 97, 112]. Randomised, controlled trials are urgently needed to generate data that clearly indicates aHSCT is superior to other, less aggressive, treatment options available, with three trials comparing aHSCT to either alemtuzumab or the best-available treatment option currently in progress. It will be of interest to note if these trials also observe an increased prevalence of autoimmune disease in their alemtuzumab populations and indeed in the cohort of patients receiving aHSCT, as this appears to be an important outcome parameter that affects a significant proportion of patients in the long term. Why this occurs is certainly a research area of interest, as is exactly how immune reconstitution leads to restored immune tolerance in the patients who benefit from transplantation.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00415-022-11063-5.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflicts of interest The authors have no competing financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S, Hellenbrand G, Piton M, Spencer CC et al (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359):214–219. https://doi.org/10.1038/nature10251
2. International Multiple Sclerosis Genetics C, Hafler DA, Compston A, Sawcer S, Landes E, Daly MJ et al (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357(9):851–862. https://doi.org/10.1056/NEJMoa073493
3. Marrie RA (2004) Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 5(12):709–718. https://doi.org/10.1016/S1474-4422(04)00933-0
4. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359(9313):1221–1231. https://doi.org/10.1016/S0140-6736(02)08220-X
5. Guerrero BL, Sicotte NL (2020) Microglia in multiple sclerosis: friend or foe? Front Immunol 11:374. https://doi.org/10.3389/fimmu.2020.00374
6. Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15(9):545–558. https://doi.org/10.1038/nri3871
7. Ontaneda D, Fox RJ, Chataway J (2015) Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol 14(2):208–223. https://doi.org/10.1016/S1474-4422(14)02064-9
8. Huntemann N, Rolfs L, Pawlitzi M, Ruck T, Pfeuffer S, Wiendel H et al (2021) Failed, interrupted, or inconclusive trials on neuroprotective and neuroregenerative treatment strategies in multiple sclerosis: update 2015–2020. Drugs 81(9):1031–1063. https://doi.org/10.1007/s40265-021-01526-w
9. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286. https://doi.org/10.1212/WNL.0000000000000560
10. Filippi M, Bar-Or A, Piehl F, Previosa P, Solari A, Vukusic S et al (2018) Multiple sclerosis. Nat Rev Dis Primers 4(1):43. https://doi.org/10.1038/s41572-018-0041-4
11. Kavrochorianou N, Markogiannaki M, Haralambous S (2016) IFN-beta differentially regulates the function of T cell subsets in neuroinflammation. Brain Behav Immun 53:109–118. https://doi.org/10.1016/j.bbi.2015.04.007
12. Stinissen P, Raus J, Zhang J (1997) Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit Rev Immunol 17(1):33–75. https://doi.org/10.1016/0145-7938(97)00014-9
13. Martin-Saavedra FM, Gonzalez-Garcia C, Bravo B, Ballester S (2008) Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol 45(15):4008–4019. https://doi.org/10.1016/j.molimm.2008.06.006
14. Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, Higgins SC et al (2011) IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun 25(6):1170–1181. https://doi.org/10.1016/j.bbi.2011.03.007
15. Ando DG, Clayton J, Kono D, Urban JL, Sercarz EE (1989) Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 124(1):132–143. https://doi.org/10.1016/0008-8749(89)90117-2

@Springer
16. Kunkl M, Frascolla S, Amorimino C, Volpe E, Tuosto L (2020) T helper cells: the modulators of inflammation in multiple sclerosis. Cells. https://doi.org/10.3390/cells9020482
17. Huseby ES, Huseby PG, Shah S, Smith R, Stadinski BD (2012) Pathogenic CD8 T cells in multiple sclerosis and its experimental models. Front Immunol 3:64. https://doi.org/10.3389/fimmu.2012.00064
18. Zozulya AL, Wiendl H (2008) The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 4(7):384–398. https://doi.org/10.1038/ncpneuro0832
19. Ruck T, Bock S, Pfeuffer S, Schroeter CB, Cengiz D, Marciniak P et al (2022) KP18.1 translates T cell receptor signals into thymic regulatory T cell development. Cell Res 32(1):72–88. https://doi.org/10.1038/s41422-021-00580-z
20. Comi G, Bar-Or A, Lassmann H, Uccelli A, Hartung HP, Montalban X et al (2021) Role of B cells in multiple sclerosis and related disorders. Ann Neurol 89(1):13–23. https://doi.org/10.1002/ana.25927
21. Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG (2017) Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord 10(1):51–66. https://doi.org/10.1177/175628561666741
22. Mimpem M, Smolders J, Hupperts R, Damoiseaux J (2020) Natural killer cells in multiple sclerosis: a review. Immunol Lett 222:1–11. https://doi.org/10.1016/j.imlet.2020.02.012
23. Calabresi PA, Kiesiear BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J et al (2014) Pegylated interferon-beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 13(7):657–665. https://doi.org/10.1016/S1474-4422(14)70068-7
24. Khan O, Rieckmann P, Boyko A, Selmaj K, Ashstamer N, Davis MD et al (2017) Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Mult Scler 23(6):818–829. https://doi.org/10.1177/1352458516664003
25. Wolinsky JS, Borresen TE, Dietrich DW, Wynn D, Sidi Y, Steinerman JR et al (2015) GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 4(4):370–376. https://doi.org/10.1016/j.msard.2015.06.005
26. Palace J, Duddy M, Lawton M, Bregenzer T, Zhu F, Boggild M et al (2019) Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. J Neurol Neurosurg Psychiatry 90(3):251–260. https://doi.org/10.1136/jnnp-2018-318360
27. Lunemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H (2020) Author Correction: Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 16(2):125. https://doi.org/10.1038/s41582-020-0310-1
28. Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A et al (2019) Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA Neurol 321(2):175–187. https://doi.org/10.1001/jama.neurol.2018.20588
29. Cree BAC, Mares J, Hartung HP (2019) Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol 32(3):365–377. https://doi.org/10.1097/WCO.0000000000000700
30. Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F et al (2019) Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 76(5):536–541. https://doi.org/10.1001/jama.neurol.2018.4905
31. Li H, Hu F, Zhang Y, Li K (2020) Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol 267(12):3489–3498. https://doi.org/10.1007/s00415-019-09395-w
32. Hartung HP, Meuth SG, Thompson AJ (2021) Paradigm shifts: early initiation of high-efficacy disease-modifying treatment in multiple sclerosis. Mult Scler 27(10):1473–1476. https://doi.org/10.1177/13524585211033190
33. University of California SFMSET, Cree BAC, Hollebahn JA, Bove R, Kirkish G, Sacco S et al (2019) Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol 85(5):653–666. https://doi.org/10.1002/ana.25463
34. Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H et al (2019) Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol 76(12):1474–1483. https://doi.org/10.1001/jamaneurol.2019.2399
35. Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R (2017) Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol 13(7):391–405. https://doi.org/10.1038/nrneurol.2017.81
36. Visweswaran M, Hendrawan K, Massey JC, Khou ML, Ford CD, Zaunders JJ et al (2022) Sustained immunotolerance in multiple sclerosis after stem cell transplant. Ann Clin Transl Neurol 9(2):206–220. https://doi.org/10.1002/acn3.51510 (Epub 2022 Feb 1, PMID: 35109691; PMCID: PMC8862434)
37. Juric MK, Ghimire S, Ogonek J, Weissinger EM, van der Meche FG et al (2006) Intense T cell depletion and autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant 55(2):283–306. https://doi.org/10.1038/s41409-019-0684-0
38. Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D et al (2020) Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with severe multiple sclerosis. Blood 102(7):2364–2372. https://doi.org/10.1182/blood-2002-12-3908
39. Burt RK, Burns W, Hess A (1995) Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 16(1):1–6
40. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V et al (1997) Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 20(8):631–638. https://doi.org/10.1038/s41409-019-0684-0
41. Burt RK, Traynor AE, Cohen B, Karlin KH, Davis FA, Stetski D et al (1998) T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 21(6):537–541. https://doi.org/10.1038/sj.bmt.1700944
42. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS et al (2003) High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102(7):2364–2372. https://doi.org/10.1182/blood-2002-12-3908
43. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y et al (2003) Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102(7):2373–2378. https://doi.org/10.1182/blood-2003-03-0877
44. Samijn JP, te Boekhorst PA, Mondria T, van Doorn PA, Flach HZ, van der Meche FG et al (2006) Intensive T cell depletion followed by autologous bone marrow transplantation for severe
progressive multiple sclerosis. Mult Scler 27(1):61–70. https://doi.org/10.1177/135245852092392
72. Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP et al (2012) Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multicentre experience. Mult Scler 18(6):835–842. https://doi.org/10.1177/1352458511429320
73. Krasulova E, Trneny M, Kozak T, Vackova B, Pohlreich D, Kem-72. Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP et al (2012) Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multicentre experience. Mult Scler 18(6):835–842. https://doi.org/10.1177/1352458511429320
74. Mariotti A, Bulgarini G, Forci B, Innocenti C, Mealli F, Mattei A et al (2022) Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis. Eur J Neurol. https://doi.org/10.1111/ene.15280 (Epub ahead of print. PMID: 35146841)
75. Comini-Frota ER, Marques BCC, Torres C, Cohen KMS, Miranda EC (2019) Nine-year follow up after hematopoietic stem cell transplantation in five multiple sclerosis patients. Arq Neuropsiquiatr 77(8):531–535. https://doi.org/10.1590/0004-282X20190097
76. Zhukovsky C, Sandgren S, Silfverberg T, Einarsdottir S, Tolf A, Landblom AM et al (2021) Autologous haematopoietic stem cell transplantation compared with alentuzumab for relapsing-remitting multiple sclerosis: an observational study. J Neurol Neurosurg Psychiatry 92(2):189–194. https://doi.org/10.1136/jnnp-2020-323992
77. Kvistad SAS, Lehmann AK, Trovik LH, Kristoffersen EK, Bo L, Myhr KM et al (2020) Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Mult Scler 26(14):1889–1897. https://doi.org/10.1177/1352458519893926
78. Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K et al (2015) Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA 313(3):275–284. https://doi.org/10.1001/jama.2014.17986
79. Burt RK, Han X, Quigley K, Helenowski IB, Balabanov R (2021) Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis. J Neurol. https://doi.org/10.1007/s00415-021-10820-2
80. Boffa G, Massacesi L, Inglese M, Mariotti A, Capobianco M, Lucia M et al (2021) Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology. https://doi.org/10.1212/WNL.0000000000011461
81. Frau J, Carai M, Coghe G, Fenu G, Lorefice L, La Nasa G et al (2018) Long-term follow-up more than 10 years after HSCT: a monocentric experience. J Neurol 265(2):410–416. https://doi.org/10.1007/s00415-017-8718-2
82. Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fas-80. Bozza P, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassia A et al (2017) Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol 74(4):459–469. https://doi.org/10.1001/jamaneurol.2016.5867
83. Das J, Snowden JA, Burman J, Freedman MS, Atkins H, Bowman M et al (2021) Autologous hematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with “aggressive” multiple sclerosis. Mult Scler 27(8):1198–1204. https://doi.org/10.1177/1352458520958538
84. Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P et al (2014) Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 85(10):1116–1121. https://doi.org/10.1136/jnnp-2013-307207
85. Tolf A, Fagius J, Carlson K, Akerfeldt T, Granberg T, Larsson EM et al (2019) Sustained remission in multiple sclerosis after hematopoietic stem cell transplantation. Acta Neurol Scand 140(5):320–327. https://doi.org/10.1111/jane.13147
86. Nicholas RS, Rhone EE, Mariotti A, Silber E, Malik O, Singh-Curry V et al (2021) Autologous hematopoietic stem cell transplantation in active multiple sclerosis: a real-world case series. Neurology 97(9):e890–e901. https://doi.org/10.1212/WNL.0000000000012449
87. Mancardi G, Saccardi R (2008) Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 7(7):626–636. https://doi.org/10.1016/S1474-4228(08)70138-8
88. Neurotoxicity of chemotherapy. Nat Clin Pract Neurol. 2007;3(3):125. https://doi.org/10.1038/ncpneuro0418
89. Amato AA, Dumitru D (2002) Chapter 23—acquired neuropa-thies. In: Dumitru D, Amato AA, Zwarts M (eds) Eletrodiagnosis medicine, 2nd edn. Hanley & Belfus, Boston, pp 937–1041
80. Boffa G, Massacesi L, Inglese M, Mariotti A, Capobianco M, Lucia M et al (2021) Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis: a review on behalf of the EBMT autoimmune diseases working party. Front Immunol 12:813957. https://doi.org/10.3389/fimmu.2021.813957
81. Goverman JM (2011) Immune tolerance in multiple sclerosis. Immunol Rev 241(1):228–240. https://doi.org/10.1111/j.1600-065X.2011.01016.x
82. Goverman JM, Regulatory T (2021) Cells in multiple sclerosis. Proc Natl Acad Sci U S A. 2012;109(3):125. https://doi.org/10.1038/pr.2011.57
83. Cencioni MT, Genchi A, Brittain G, de Silva TL, Sharrack B, Snowden JA et al (2021) Immune reconstitution following autologous hematopoietic stem cell transplantation for multiple sclerosis: a review on behalf of the EBMT autoimmune diseases working party. Front Immunol 12:813957. https://doi.org/10.3389/fimmu.2021.813957
84. Abrahamsson SV, Angelini DF, Dubinsky AN, Morel E, Oh U, Jones JL et al (2013) Non-myeloablative autologous haemat-opietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 136(Pt 9):2888–2903. https://doi.org/10.1093/brain/awt182
85. Jaime-Perez JC, Turrubiates-Hernandez GA, Lopez-Silva LJ, Salazar-Riojas R, Gomez-Almaguer D (2020) Early changes in IL-21, IL-22, CCL2, and CCL4 serum cytokines after outpatient autologous transplantation for multiple sclerosis: a proof of concept study. Clin Transplant 34(12):e14114. https://doi.org/10.1111/ctr.14114
86. Darlington PJ, Stopnicki B, Toull T, Doucet JS, Favaz L, Roberts ME et al (2018) Natural killer cells regulate Th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis. Front Immunol 9:834. https://doi.org/10.3389/fimmu.2018.00834
87. Larochelle C, Wasser B, Jamann H, Loeffl JT, Cui QL, Tastet O et al (2021) Pro-inflammatory T helper 17 directly harms oligodendrocytes in neuroinflammation. Proc Natl Acad Sci U S A. https://doi.org/10.1073/pnas.2025813118
101. Harris KM, Lim N, Lindau P, Robins H, Griffith LM, Nash RA et al (2020) Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis. JCI Insight. https://doi.org/10.1172/jci.insight.127655

102. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Casissian-Ingoni R et al (2005) Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 201(5):805–816. https://doi.org/10.1084/jem.20041679

103. Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, Kasten-Sportes C et al (2005) Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 115(4):930–939. https://doi.org/10.1172/JCI22492

104. Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, Desmarais C et al (2014) T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest 124(3):1168–1172. https://doi.org/10.1172/JCI71691

105. Gaballa A, Clave E, Uhlin M, Toubert A, Arruda LCM (2020) Evaluating thymic function after human hematopoietic stem cell transplantation in the personalized medicine era. Front Immunol 11:1341. https://doi.org/10.3389/fimmu.2020.01341

106. Amoriello R, Greiff V, Aldinucci A, Bonechi E, Carnasciali A, Peruzzi B et al (2020) The TCR repertoire reconstitution in multiple sclerosis: comparing one-shot and continuous immunosuppressive therapies. Front Immunol 11:559. https://doi.org/10.3389/fimmu.2020.00559

107. Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnold DL et al (2006) Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 66(12):1935–1937. https://doi.org/10.1212/01.wnl.000019816.44094.f8

108. Inglese M, Mancardi GL, Pagani E, Rocca MA, Murialdo A, Saccardi R et al (2004) Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 75(4):643–644

109. Rocca MA, Mondria T, Valsasina P, Sormani MP, Flach ZH, Te Boekhorst PA et al (2007) A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR Am J Neuroradiol 28(9):1659–1661. https://doi.org/10.3174/ajnr.A0644

110. Mariottiini A, Marchi L, Innocenti C, Di Cristinzi M, Pasca M, Filippini S et al (2022) Intermediate-intensity autologous hematopoietic stem cell transplantation reduces serum neurofilament light chains and brain atrophy in aggressive multiple sclerosis. Front Neurol 13:820256. https://doi.org/10.3389/fneur.2022.820256 (PMID: 35280289; PMCID: PMC8907141)

111. Meca-Lallana V, Berenguer-Ruiz L, Carreres-Polo J, Eichau- Madueno S, Ferrer-Lozano J, Forero L et al (2021) Deciphering multiple sclerosis progression. Front Neurol 12:608491. https://doi.org/10.3389/fneur.2021.608491

112. Arruda LCM, de Azevedo JTC, de Oliveira GLV, Scortegagna GT, Rodrigues ES, Palma PVB et al (2016) Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation. Clin Immunol 169:47–57. https://doi.org/10.1016/j.clim.2016.06.005